|
Q1 FY2026
As of Dec 31, 2025
|
Q4 FY2025
As of Sep 30, 2025
|
Q3 FY2025
As of Jun 30, 2025
|
Q2 FY2025
As of Mar 31, 2025
|
Q1 FY2025
As of Dec 31, 2024
|
Q4 FY2024
As of Sep 30, 2024
|
Q3 FY2024
As of Jun 30, 2024
|
Q2 FY2024
As of Mar 31, 2024
|
Q1 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Sep 30, 2023
|
Q3 FY2023
As of Jun 30, 2023
|
Q2 FY2023
As of Mar 31, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 30, 2022
|
Q3 FY2022
As of Jun 30, 2022
|
Q2 FY2022
As of Mar 31, 2022
|
Q1 FY2022
As of Dec 31, 2021
|
Q4 FY2021
As of Sep 30, 2021
|
Q3 FY2021
As of Jun 30, 2021
|
Q2 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Trade receivables, net | ||||||||||||||||||||
| Receivables from long-term manufacturing contracts, net | ||||||||||||||||||||
| Inventories, net | ||||||||||||||||||||
| Current assets held for sale | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant, and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Equity method investments | ||||||||||||||||||||
| Long-term assets held for sale | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Trade accounts payable | ||||||||||||||||||||
| Liabilities from long-term manufacturing contracts and advances | ||||||||||||||||||||
| Current portion of long-term debt | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Disposal Group, Including Discontinued Operation, Liabilities, Current | ||||||||||||||||||||
| Current liabilities held for sale | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Accrued pension and postretirement healthcare | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Long-term liabilities held for sale | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| SHAREHOLDERS’ EQUITY | ||||||||||||||||||||
| Common stock, no par value (75.8 and 75.8 shares issued, 70.7 and 70.2 shares outstanding) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock (5100000 and 5300000 shares, at cost) | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Hillenbrand Shareholders’ Equity | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total Shareholders’ Equity | ||||||||||||||||||||
| Total Liabilities and Shareholders’ Equity | ||||||||||||||||||||
| Equity Method Investments |
Loading...
